{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:40:35Z","timestamp":1792168835758,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s10067-019-04875-w","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T08:02:44Z","timestamp":1577952164000},"page":"847-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":139,"title":["JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis"],"prefix":"10.1007","volume":"39","author":[{"given":"Elisabetta","family":"Miserocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Giuffr\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cornalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pontikaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"4875_CR1","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.ophtha.2009.05.002","volume":"116","author":"JA Smith","year":"2009","unstructured":"Smith JA, Mackensen F, Sen HN et al (2009) Epidemiology and course of disease in childhood uveitis. Ophthalmology 116:1544\u20131551","journal-title":"Ophthalmology"},{"key":"4875_CR2","first-page":"1107","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C, Gepstein R, Heiligenhaus A, Pilkington CA, Simonini G, Uziel Y, Vastert SJ, Wulffraat NM, Haasnoot AM, Walscheid K, P\u00e1link\u00e1s A, Pattani R, Gy\u00f6rgyi Z, Kozma R, Boom V, Ponyi A, Ravelli A, Ramanan AV (2018) Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis 77:1107\u20131117","journal-title":"Ann Rheum Dis"},{"key":"4875_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40674-017-0057-z","volume":"3","author":"AB Sood","year":"2017","unstructured":"Sood AB, Angeles-Han ST (2017) An update on treatment of pediatric chronic non-infectious uveitis. Curr Treatm Opt Rheumatol 3:1\u201316","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"4875_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/ICU.0000000000000559","volume":"30","author":"J Gueudry","year":"2019","unstructured":"Gueudry J, Touhami S, Quartier P, Bodaghi B (2019) Therapeutic advances in juvenile idiopathic arthritis - associated uveitis. Curr Opin Ophthalmol 30:179\u2013186","journal-title":"Curr Opin Ophthalmol"},{"key":"4875_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/archdischild-2018-315060","volume":"104","author":"A Skrabl-Baumgartner","year":"2019","unstructured":"Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J (2019) Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child 104:246\u2013250","journal-title":"Arch Dis Child"},{"key":"4875_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.12703\/P6-41","volume":"6","author":"BA Wentworth","year":"2014","unstructured":"Wentworth BA, Freitas-Neto CA, Foster CS (2014) Management of pediatric uveitis. F1000Prime Rep 6:41","journal-title":"F1000Prime Rep"},{"issue":"19","key":"4875_CR7","doi-asserted-by":"publisher","first-page":"30274","DOI":"10.1016\/j.ajo.2019.06.007","volume":"S0002-9394","author":"S Horton","year":"2019","unstructured":"Horton S, Jones AP, Guly CM et al (2019) Adalimumab in juvenile-idiopathic arthritis-associated uveitis (JIA-U): 5-year follow-up of the Bristol participants of the SYCAMORE trial. Am J Ophthalmol S0002-9394(19):30274\u201330270. https:\/\/doi.org\/10.1016\/j.ajo.2019.06.007","journal-title":"Am J Ophthalmol"},{"key":"4875_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ophtha.2018.09.043","volume":"126","author":"DA Hughes","year":"2019","unstructured":"Hughes DA, Culeddu G, Plumpton CO, Wood E, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot Lacassagne S, Hardwick B, Hickey H, Woo P, Beresford MW, Ramanan AV (2019) Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis. Ophthalmology 126:415\u2013424","journal-title":"Ophthalmology"},{"key":"4875_CR9","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/bjophthalmol-2015-306790","volume":"100","author":"E Miserocchi","year":"2016","unstructured":"Miserocchi E, Modorati G, Berchicci L, Pontikaki I, Meroni P, Gerloni V (2016) Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol 100:782\u2013786","journal-title":"Br J Ophthalmol"},{"key":"4875_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/jcpt.12821","volume":"44","author":"V Dipasquale","year":"2019","unstructured":"Dipasquale V, Atteritano M, Fresta J (2019) Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: a report of two cases. J Clin Pharm Ther 44:482\u2013485","journal-title":"J Clin Pharm Ther"},{"key":"4875_CR11","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3899\/jrheum.160231","volume":"43","author":"C Tappeiner","year":"2016","unstructured":"Tappeiner C, Mesquida M, Ad\u00e1n A, Anton J, Ramanan AV, Carreno E, Mackensen F, Kotaniemi K, de Boer JH, Bou R, de Vicu\u00f1a CG, Heiligenhaus A (2016) Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 43:2183\u20132188","journal-title":"J Rheumatol"},{"key":"4875_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3899\/jrheum.140410","volume":"42","author":"C Tappeiner","year":"2015","unstructured":"Tappeiner C, Miserocchi E, Bodaghi B, Kotaniemi K, Mackensen F, Gerloni V, Quartier P, Lutz T, Heiligenhaus A (2015) Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 42:706\u2013711","journal-title":"J Rheumatol"},{"key":"4875_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11926-018-0792-7","volume":"20","author":"SA Kerrigan","year":"2018","unstructured":"Kerrigan SA, McInnes IB (2018) JAK inhibitors in rheumatology: implication for paediatric syndromes? Curr Rheumatol Rep 20:83","journal-title":"Curr Rheumatol Rep"},{"key":"4875_CR14","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigbt W, Azevedo VF et al (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377:1525\u20131536","journal-title":"N Engl J Med"},{"key":"4875_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2217\/imt-2018-0178","volume":"11","author":"J Jegatheeswaran","year":"2019","unstructured":"Jegatheeswaran J, Turk M, Pope JE et al (2019) Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Immunotherapy 11:737\u2013754","journal-title":"Immunotherapy"},{"issue":"supplement 1","key":"4875_CR16","doi-asserted-by":"publisher","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","volume":"58","author":"M Harigai","year":"2019","unstructured":"Harigai M (2019) Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 58(supplement 1):i34\u2013i42","journal-title":"Rheumatology (Oxford)"},{"key":"4875_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2019.1605453","volume":"3","author":"P Bauermann","year":"2019","unstructured":"Bauermann P, Heiligenhaus A, Heinz C (2019) Effect of Janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm 3:1\u20133. https:\/\/doi.org\/10.1080\/09273948.2019.1605453","journal-title":"Ocul Immunol Inflamm"},{"key":"4875_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/ICO.0000000000000019","volume":"33","author":"W Stevenson","year":"2014","unstructured":"Stevenson W, Sadrai Z, Hua J, Kodati S, Huang JF, Chauhan SK, Dana R (2014) Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity. Cornea 33:177\u2013183","journal-title":"Cornea"},{"key":"4875_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","volume":"13","author":"MA Paley","year":"2018","unstructured":"Paley MA, Karacal H, Rao PK et al (2018) Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 13:53\u201355","journal-title":"Am J Ophthalmol Case Rep"},{"key":"4875_CR20","first-page":"509","volume":"140","author":"DA Jabs","year":"2015","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT (2015) Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509\u2013516","journal-title":"Am J Ophthalmol"},{"key":"4875_CR21","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P, International League of Associations for Rheumatology (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390\u2013392","journal-title":"J Rheumatol"},{"key":"4875_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10067-017-3890-4","volume":"37","author":"CK Correll","year":"2018","unstructured":"Correll CK, Bullock DR, Cafferty RM et al (2018) Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol 37:549\u2013553","journal-title":"Clin Rheumatol"},{"key":"4875_CR23","unstructured":"Eli Lilly and Company.A study of baricitinib (LY3009104) in participants from 2 years to less than 18 years old with active JIA-associated uveitis or chronic anterior antinuclear antibody-positive uveitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04088409.ClinicaltrialsGovIdentifier:NCT04088409"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04875-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T20:23:48Z","timestamp":1609446228000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04875-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["4875"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04875-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"24 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}